股价大涨150%，这家“凤凰之星”获奖企业做对了什么？

Group 1 - The core viewpoint of the article highlights the significant growth and recognition of Kangfang Biotech, which has seen its stock price increase by over 150% since winning the "Most Growth-Oriented Listed Company" award in the Hong Kong stock market [1][2] - Kangfang Biotech reported a revenue of 1.412 billion yuan for the first half of 2025, representing a year-on-year growth of 33.7% [2] - The company aims to accelerate innovation value transformation and establish global innovation barriers through strategies such as product commercialization and international expansion [2][3] Group 2 - The Chinese innovative drug market has experienced a significant surge this year, driven by factors such as accelerated new drug approvals and the international expansion of Chinese pharmaceutical companies [4] - Kangfang Biotech's core product, Iwosimab, has achieved a notable victory against a global competitor, enhancing the perception of China's biopharmaceutical innovation capabilities [4][5] - The overseas licensing transactions for Chinese innovative drugs reached approximately 66 billion dollars in the first half of 2025, indicating a strong market trend [4][5] Group 3 - The "Phoenix Star" award emphasizes the core competitiveness and long-term impact of companies on the industry, distinguishing it from other awards [7] - The recognition from the "Phoenix Star" award serves as both an incentive and a motivation for Kangfang Biotech to continue investing in source innovation [7]